刘龙飞，男，汉族，1983年生，江西吉安人，医学博士，中南大学湘雅医院泌尿外科副教授，主任医师，副研究员，硕士研究生导师，美国UCLA访问学者，湖南省高层次卫生人才“225”工程培养对象，湖南省青年骨干教师，入选中南大学升华育英人才计划。2019年2月-2021年8月任中南大学湘雅医院学科建设办公室主任。2021年6月起，任中南大学湘雅医院党委委员、副院长。主攻肾上腺肿瘤与继发性高血压、泌尿系统与腹膜后肿瘤及泌尿系统修复重建，擅长微创泌尿外科手术，多次获邀在全国性会议上进行手术演示与大会报告。

主持国家自然科学基金2项，以第一或通讯作者在等国际知名期刊发表SCI论文20余篇，获省级科技奖励4项、中南大学及湘雅医院医疗成果奖10余项，为2015年全国百篇优秀医学教学论文奖获得者。致力于嗜铬细胞瘤/副神经节瘤（PPGL）发病机制与临床转化研究，作为核心成员建立了大型PPGL专病队列，牵头或参与的多项国际多中心研究初步绘制了中国汉族人PPGL致病基因突变谱；修正了儿茶酚胺代谢调控“基因决定学说”；提出了帮助嗜铬细胞瘤孕妇诞下健康宝宝的新疗法；论证了遗传性嗜铬细胞瘤“保留肾上腺皮质”手术策略。系列研究成果发表在The Lancet Diabetes & Endocrinology、JAMA Network Open、JCEM等国际著名期刊。毕业研究生4名，在读硕士研究生3名，参与培养博士、硕士10余名。

 Liu Longfei, male, Han nationality, born in 1983, Ji 'an, Jiangxi Province,  doctor of medicine, associate professor of urology, chief physician, associate researcher, postgraduate tutor, visiting scholar of UCLA in the United States, training target of "225" project for high-level health talents in Hunan Province, young backbone teacher in Hunan Province, was selected as the talent program of sublimation and education in Central South University. From February 2019 to August 2021, he served as director of discipline construction office of Xiangya Hospital of Central South University. Since June 2021, he has served as Party Committee member and vice president of Xiangya Hospital of Central South University. He specializes in adrenal tumors and secondary hypertension, urinary system and retroperitoneal tumors, and urinary system repair and reconstruction. He is good at minimally invasive urology and has been invited to give surgical presentations and conference reports at national conferences for many times. He presided over 2 projects of the National Natural Science Foundation of China, published more than 20 SCI papers by the first or correspondent authors in other internationally renowned journals, won 4 provincial science and technology awards, and more than 10 medical achievement awards of Central South University and Xiangya Hospital, and was the winner of the 2015 National Top 100 Medical Teaching Papers Award. Committed to the study of pathogenesis and clinical transformation of pheochromocytoma/paraganglioma (PPGL), as a core member, established a large-scale PPGL disease-specific cohort, and preliminarily mapped the mutation spectrum of PPGL pathogenic genes of Chinese Han people in a number of international multicenter studies led or participated in; Corrected the "gene determination theory" of catecholamine metabolism regulation; Put forward a new therapy to help pregnant women with pheochromocytoma give birth to healthy babies. The surgical strategy of "adrenocortical preservation" for hereditary pheochromocytoma was demonstrated. Series of research results have been published in the Lancet Diabetes & Endocrinology, JAMA Network Open, JCEM and other internationally renowned journals. There are 4 graduate students, 3 postgraduate students, and more than 10 doctors and masters.